drugset
drugset / Trial / NCT06947993

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

NCT06947993 ↗

Phase 2 Recruiting 224 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).

Timeline

Start
2025-05-16
Primary completion
2028-11-27
Completion
2028-12-22

Drugs

EvaluationDrugModalityDoseRoute
Subject GHZ339 Unknown — —

Indications

atopic eczema